Ilya I. Serebriyskiy

TL;DR: The VTE incidence rate in women from developed countries for both antepartum and postpartum periods and for subpopulations of women affected by additional risk factors, such as thrombophilias, circulatory diseases, preeclampsia of varying degrees of severity, and Caesarean section is discussed.

TL;DR: Thrombodynamics (TD) is shown to reliably characterize the pharmacodynamics of any heparin in the entire range of its prophylactic and therapeutic concentrations and has advantages over the other global methods of coagulation analysis.

TL;DR: The state-of-the-art knowledge of the molecular changes in the hemostatic system in normal pregnancy and during pregnancy-related complications is reviewed, and the sensitivity of various classic and innovative assays to these pregnancy-associated changes are discussed.

TL;DR: Results indicate that TD has a high sensitivity to the effects of UFH and LMWH after both prophylactic and therapeutic regimes and may be used for heparin monitoring.

TL;DR: Estimating the potency of tests to reflect the coagulation state of patients receiving low-molecular-weight heparin prophylaxis in the early postpartum period is potentially beneficial for the application of thrombodynamics and throm bodynamics-4D in monitoring coagulated among patients with high VTE risk who receive thromboprophylaxis with heparIn.